Axsome: The Alzheimer's Agitation Program For AXS-05
Axsome's AXS-05 shows strong efficacy in treating Alzheimer's Disease Agitation, with significant CMAI score reductions.
Medical Dialogues8d
Alembic Global Holding incorporates wholly-owned subsidiary in USA
Vadodara: Alembic Global Holding SA, a wholly owned subsidiary of Alembic Pharmaceuticals Limited has incorporated a wholly-owned subsidiary in USA, named Alembic Lifesciences Inc.
EC approves Otsuka and Lundbeck’s Rxulti for schizophrenia
The decision was supported by a randomised, six-week, placebo-controlled trial involving 316 adolescent subjects.
The Pharma Letter13d
Rxulti now approved for adolescents in Europe
The European Commission (EC) has approved Danish CNS specialist Lundbeck (LUND: CO) and Otsuka Europe’s Rxulti ...
PharmaTimes13d
Rxulti approved in the European Union for adolescent schizophrenia
Otsuka Pharmaceutical Europe and Lundbeck have announced that the European Commission has approved Rxulti (brexpiprazole) for ...
Rxulti® (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older
Otsuka Pharmaceutical Europe Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced that the European Commission (EC) has approved Rxulti® (brexpiprazole) for the treatment of schizophrenia in ...
H. Lundbeck A/S: Rxulti (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older
Brexpiprazole's indication for the treatment of schizophrenia in adults is extended to include adolescents aged 13 years and older1Approval follows a positive Committee for Medicinal Products ...